samedan logo

 
 
spacer
home > pmps > autumn 2003 > knowledge sharing in the clinical trials industry - annex 13
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Knowledge Sharing in the Clinical Trials Industry - Annex 13

Let us start with the core functions provided by BlisTech UK.

BlisTech Clinical Trial Packaging Ltd's primary function is to provide a comprehensive clinical trial packaging service, providing primary and secondary packaging in a variety of presentations. BlisTech also provide storage, distribution and have two qualified persons (QPs) available for batch release under 75/319/EEC (2001/183/EEC). We also package and provide QP release for commercial products.

In our recent interview with Joseph Saccamono (PMPS Spring 2003) we talked about the aspect of technical knowledge sharing. How has that changed the demands of the European pharmaceutical companies?

Annex 13 has been the classic case where technical knowledge sharing has been crucial. The pharma business has had to wake up to the new GMP requirements to ensure they will be able to initiate and/or continue their clinical trials in May 2004. BlisTech has been sharing information in preparation for QP certification of batches for IMPs in 2004 with new and existing clients, as and when necessary. BlisTech have also employed two QPs to ensure their clients' needs will be met and will be applying for the new IMP Licence when the application forms are released by the MHRA.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
PMPS talks to Jill Warr, Quality Manager and QP at BlisTech UK

Jill Warr graduated with a BSC (Hons) in Combined Science and later obtained a PGDIPS, both from Brighton University, UK. Under permanent transition Jill became eligible for nomination as a QP under the provisions of Directive 75/319/EEC and 81/851/EEC. She became Operational Quality Manger and QP for GlaxoWellcome and GlaxoSmithKline, Dartford UK in 1996 before joining BlisTech UK as Quality Manager and QP in May 2003. Previous experience within the pharmaceutical industry includes formulation development with sterile, solid dose, liquid and cream pharmaceutical formulations, packaging technology and clinical trial packaging.

spacer
Jill Warr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

UBC APPOINTS BEKKI BROWN PRESIDENT & CHIEF EXECUTIVE OFFICER

Effective January 1, 2023, Bekki Brown will assume the role of President & Chief Executive Officer of UBC
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement